[Effects of silymarin and its combination with succinic acid on brain bioenergetics in rats with experimental inhibition of beta-oxidation of fatty acids].
In the tests on rats with a model of encephalopathy caused by 4-pentenoic acid (inhibitor of the beta-oxidation of fatty acids), the hepatoprotective agent silymarin increases the respiratory activity in brain mitochondria, improves oxidative phosphorylation coupling and energization, and inhibits lipid peroxidation. Succinic acid (a regulator of bioenergetics) improves the damaged Krebs cycle metabolic pathways and produces an antioxidant effect. The combined use of silymarin and succinic demonstrated more expressed cerebroprotective action as compared to that of each agent administered separately.
Vengerovskiĭ
A I
AI
Khazanov
V A
VA
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004357:Drug Synergism; D004734:Energy Metabolism; D005227:Fatty Acids / Q000378:metabolism*; D005229:Fatty Acids, Monounsaturated; D006501:Hepatic Encephalopathy / Q000139:chemically induced / Q000378:metabolism*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010084:Oxidation-Reduction; D010085:Oxidative Phosphorylation; D051381:Rats; D012838:Silymarin / Q000494:pharmacology*; D019802:Succinic Acid / Q000627:therapeutic use*
D000975:Antioxidants; D005227:Fatty Acids; D005229:Fatty Acids, Monounsaturated; D018696:Neuroprotective Agents; D012838:Silymarin; D019802:Succinic Acid; C009785:4-pentenoic acid